Citations

Clear

912 citation(s) found for "Yu, Caroline".

Stress Echo 2030: The Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
Pepi, Mauro , Ciampi, Quirino , Cortigiani, Lauro , Arruda‐Olson, Adelaide M. , Daros, Clarissa Borguezan , Pretto, José Luis de Castro e Silva , Bossone, Eduardo , Merli, Elisa , Kane, Garvan C. , Scali, Maria Chiara, Morrone, Doralisa , Simova, Iana , Samardjieva, Martina, Boshchenko, A , Ryabova, T. R. , Pálinkás, Eszter Dalma , Sepp, Róbert , Torres, Marco Antônio Rodrigues , Villarraga, Hector R. , Kovačević-Preradović, Tamara , Citro, Rodolfo , Amor, Miguel , Mosto, Hugo , Salamè, Michael, Leeson, Paul , Gaibazzi, Nicola , Tuttolomondo, Domenico , Prota, Costantina , Peteiro, Jesús , Heyning, Caroline M. Van De , D’Andrea, Antonello , Rigo, Fausto , Ostojić, Miodrag , Arbucci, Rosina , Haber, Diego M. Lowenstein, Merlo, Pablo , Wierzbowska‐Drabik, Karina , Kasprzak, Jarosław D. , Haberka, Maciej , Ratanasit, Nithima , Mori, Fabio , D’Alfonso, Maria Grazia , Tassetti, Luigi , Milazzo, Alessandra , Olivotto, Iacopo , Marchi, Alberto, Rodríguez‐Zanella, Hugo , Zagatina, A , Padang, Ratnasari , Dekleva, Milica , Djordievic-Dikic, Ana, Boskovic, N , Tešić, Milorad , Giga, Vojislav , Salvo, Giovanni Di , Lorenzoni, Valentina , Cameli, Matteo , Bombardini, Tonino, Caso, Pio, Čelutkienė, Jelena , Barbieri, Andréa , Benfari, Giovanni , Bartolacelli, Ylenia , Malagoli, Alessandro , Mantovani, Francesca , Villari, Bruno, Russo, Antonello , Nes, Michele De, Carpeggiani, Clara , Monte, Ines , Re, Federica , Cotrim, Carlos , Bilardo, G, Karužas, Arnas , Matuliauskas, D, Colonna, Paolo , Antonini‐Canterin, Francesco, Pellikka, Patricia A. , (SIECVI), The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging, Borguezan-Daros, Clarissa , de Castro E Silva Pretto, José Luis , Bossone, Eduardo , Morrone, Doralisa , Palinkas, Eszter Dalma , Preradović, Tamara Kovačević , Tuttolomondo, Domenico , Peteiro, Jesus , Van De Heyning, Caroline M , D'Andrea, Antonello , Arbucci, Rosina , Wierzbowska-Drabik, Karina , Tassetti, Luigi , Olivotto, Iacopo , Rodriguez-Zanella, Hugo , Tesic, Milorad , Di Salvo, Giovanni , Cameli, Matteo , Mandoli, Giulia Elena , Barbieri, Andrea , Benfari, Giovanni , Bartolacelli, Ylenia , Malagoli, Alessandro , Mantovani, Francesca , Monte, Ines , Cotrim, Carlos , Karuzas, Arnas , Colonna, Paolo , Pepi, Mauro , Pellikka, Patricia A , Ciampi, Quirino , Zagatina, Angela , Kasprzak, Jaroslaw D , Ryabova, Tamara , Gaibazzi, Nicola , Lorenzoni, Valentina , Citro, Rodolfo , Boshchenko, Alla , Celutkiene, Jelena , Cocchia, Rosangela , Varga, Albert , Ágoston, Gergely , Vrublevsky, A. V. , Pálinkás, Attila , Mangia, Cristina , Nikolic, Aleksandra, Lowenstein, Jorge , Camarozano, Ana Cristina , Marchi, Alberto, Beleslin, Branko , Bursi, Francesca , Saad, Ariel K. , (SIECVI), The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging

Mayo Clinic

Journal of Clinical Medicine | August 17, 2021 | Volume: 10 | Issue: 16 | Pages: 3641

10.3390/jcm10163641 | PMID 34441937 Get It

With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD. ABCDE protocol was the fruit of SE 2020, and is the seed of SE 2030, which is articulated in 12 projects: 1-SE in coronary artery disease (SECAD); 2-SE in diastolic heart failure (SEDIA); 3-SE in hypertrophic cardiomyopathy (SEHCA); 4-SE post-chest radiotherapy and chemotherapy (SERA); 5-Artificial intelligence SE evaluation (AI-SEE); 6-Environmental stress echocardiography and air pollution (ESTER); 7-SE in repaired Tetralogy of Fallot (SETOF); 8-SE in post-COVID-19 (SECOV); 9: Recovery by stress echo of conventionally unfit donor good hearts (RESURGE); 10-SE for mitral ischemic regurgitation (SEMIR); 11-SE in valvular heart disease (SEVA); 12-SE for coronary vasospasm (SESPASM). The study aims to recruit in the next 5 years (2021–2025) ≥10,000 patients followed for ≥5 years (up to 2030) from ≥20 quality-controlled laboratories from ≥10 countries. In this COVID-19 era of sustainable health care delivery, SE2030 will provide the evidence to finally recommend SE as the optimal and versatile imaging modality for functional testing anywhere, any time, and in any patient.
Short reply to “Proton therapy for newly diagnosed glioblastoma: more room for investigation” by R. Press et al
Chung, Caroline , Brown, Paul D. , Wefel, Jeffrey S.

Mayo Clinic

Neuro-Oncology | August 3, 2021 | Volume: 23 | Issue: 11 | Pages: 1982-1982

10.1093/neuonc/noab193 | PMID 34453547 Get It

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Auclair, Daniel , Adam, Stacey J. , Agarwal, Amit , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica R. , Connors, Dana E. , Dash, Ajeeta B. , Bacco, Alessandra Di , Ling, Du, Flores‐Montero, Juan , Ghobrial, Irene M. , Gormley, Nicole , Gupta, Ira, Higley, Howard R., Hillengaß, Jens , Kanapuru, Bindu , Kazandjian, Dickran , Kelloff, Gary J. , Kremer, Brandon E. , Lightbody, Elizabeth D. , Lomas, Oliver , Mateos, María‐Victoria , de, Rocío Montes , Mukundan, Lata , Munshi, Nikhil C. , O’Donnell, Elizabeth , Paiva, Bruno , Patel, Reshma, Pugh, Trevor J. , Ramasamy, Karthik , Ray, Jill, Roshal, Mikhail , Ross, Jeremy A. , Sigman, Caroline C. , Thoren, Katie , Trudel, Suzanne , Ulaner, Gary A. , Valente, Nancy, Weiss, Brendan M. , Zamagni, Elena , Kumar, Shaji , Adam, Stacey J , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica , Connors, Dana E , Dash, Ajeeta B , Di Bacco, Alessandra , Flores-Montero, Juan , Gay, Francesca , Hillengass, Jens , Landgren, C Ola , Lomas, Oliver C , Montes de Oca, Rocio , Pugh, Trevor J , Ramasamy, Karthik , Sigman, Caroline C , Thoren, Katie L , Paiva, Bruno , Ghobrial, Irene M , Ulaner, Gary , Gormley, Nicole , Anderson, Kenneth C. , Avet‐Loiseau, Hervé , Facon, Thierry T.F. , Gay, Francesca , Kirsch, Ilan R. , Landgren, Ola , Lonial, Sagar , Órfão, Alberto , Patel, Reshma, Zamagni, Elena

Mayo Clinic

Clinical Cancer Research | July 28, 2021 | Volume: 27 | Issue: 19 | Pages: 5195-5212

10.1158/1078-0432.ccr-21-1059 | PMID 34321279 Get It

AbstractThe development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow–based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in patients with multiple myeloma. Complementary liquid biopsy–based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid–based technologies are still developing and will prove important to further our understanding of the biology of MRD. On the regulatory front, multiple retrospective individual patient and clinical trial level meta-analyses have already shown and will continue to assess the potential of MRD as a surrogate for patient outcome. Given all this progress, it is not surprising that a number of clinicians are now considering using MRD to inform real-world clinical care of patients across the spectrum from smoldering myeloma to relapsed refractory multiple myeloma, with each disease setting presenting key challenges and questions that will need to be addressed through clinical trials. The pace of advances in targeted and immune therapies in multiple myeloma is unprecedented, and novel MRD-driven biomarker strategies are essential to accelerate innovative clinical trials leading to regulatory approval of novel treatments and continued improvement in patient outcomes.
Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores
Barnes, Daniel R. , Silvestri, Valentina , Leslie, Goska , McGuffog, Lesley, Yang, Xin , Adlard, Julian , Agnarsson, Bjarni A. , Ahmed, Munaza, Aittomäki, Kristiina, Andrulis, Irene L. , Arason, Aðalgeir , Azzollini, Jacopo , Barkardóttir, Rósa B. , Barrowdale, Daniel , Belotti, Muriel, Berthet, Pascaline, Boonen, Susanne E. , Borg, Åke , Brady, Angela F., Brewer, Carole, Brunet, Joan , Bucalo, Agostino, Caldés, Trinidad , Cassingham, Hayley , Christensen, Lise Lotte , Cini, Giulia , Claes, Kathleen , Collaborators, GEMO Study, Collaborators, EMBRACE, Cortesi, Laura , Damante, Giuseppe , Darder, Esther , Davidson, Rosemarie, Leeneer, Kim De , Putter, Robin De , Valle, Jesús Del , Ding, Yuan Chun , Donaldson, Alan , Eason, Jacqueline , Eeles, Rosalind A. , Engel, Christoph , Evans, D. Gareth , Feliubadaló, Lídia , Frone, Megan N. , Frost, Debra, Gehrig, Andrea, Giraud, Sophie , Glendon, Gord , Goldgar, David E. , Greene, Mark H. , Gregory, Helen , Groß, Eva, Hahnen, Eric, Hamann, Ute, Hansen, Thomas van Overeem , Hanson, Helen , Horváth, Judit , Investigators, KConFab, Investigators, HEBON, Izatt, Louise , James, Paul A. , Janavičius, Ramūnas , Jensen, Uffe Birk , Johannsson, Oskar T., John, Esther M. , Kramer, Gero , Kroeldrup, Lone , Kruse, Torben A. , Lautrup, Charlotte Kvist , López‐Fernández, Adrià , Mai, Phuong L, Manoukian, Siranoush , Mátrai, Zoltán , Matricardi, Laura , Mebirouk, Noura, Meindl, Alfons , Montagna, Marco , Monteiro, Álvaro N.A. , Morrison, Patrick J. , Muranen, Taru , Nathanson, Katherine L. , Niederacher, Dieter , Oláh, Edith , Olopade, Olufunmilayo I. , Pedersen, Inge Søkilde , Peissel, Bernard , Peterlongo, Paolo , Petersen, Annabeth Høgh , Pinto, Pedro, Porteous, Mary, Pottinger, Caroline , Pujana, Miquel Angel, Ramser, Juliane, Rantala, Johanna, Rogers, Mark T., Rønlund, Karina, Abajo, A.M. SÁnchez De, Shah, Payal D. , Sharif, Saba , Side, Lucy, Stadler, Zsofia, Steele, Linda , Sutter, Christian , Tan, Yen Y. , Teixeira, Manuel R. , Teulé, Àlex , Thull, Darcy L. , Trainer, Alison H., Tripathi, Vishakha , Valentini, Virginia , Viel, Alessandra , Walker, Lisa, Wang‐Gohrke, Shan , Wappenschmidt, Barbara , Whaite, Anna , Offit, Kenneth, Thomassen, Mads , Schmutzler, Rita K., Simard, Jacques , Easton, Douglas F. , Chenevix‐Trench, Georgia , Antoniou, Antonis C. , Pujana, Miguel Ángel , Dennis, Joe , Yang, Xin , Adlard, Julian , Agnarsson, Bjarni A , Andrulis, Irene L , Arason, Adalgeir , Arnold, Norbert , Auber, Bernd , Azzollini, Jacopo , Barkardottir, Rosa B , Barrowdale, Daniel , Benitez, Javier , Boonen, Susanne E , Bozsik, Aniko , Brennan, Paul , Brunet, Joan , Bucalo, Agostino , Caligo, Maria A , Campbell, Ian G , Cassingham, Hayley , Cini, Giulia , Claes, Kathleen B M , Coppa, Anna , Cortesi, Laura , Darder, Esther , de la Hoya, Miguel , de Putter, Robin , Del Valle, Jesús , Domchek, Susan M , Donaldson, Alan , Eason, Jacqueline , Engel, Christoph , Fostira, Florentia , Frone, Megan , Glendon, Gord , Godwin, Andrew K. , Greene, Mark H , Hahnen, Eric , Hanson, Helen , Izatt, Louise , Izquierdo, Angel , James, Paul , John, Esther M , Kroeldrup, Lone , Kruse, Torben A , Lazaro, Conxi , Lesueur, Fabienne , Matrai, Zoltan , Montagna, Marco , Monteiro, Alvaro N , Morrison, Patrick J , Muranen, Taru A , Nathanson, Katherine L , Neuhausen, Susan L. , Nevanlinna, H , Nguyen-Dumont, Tu , Niederacher, Dieter , Palli, Domenico , Parsons, Michael T , Perez-Segura, Pedro , Peterlongo, Paolo , Pinto, Pedro , Pottinger, Caroline , Radice, Paolo , Robson, Mark , Rump, Andreas , Sharif, Saba , Steele, Linda , Stoppa-Lyonnet, Dominique , Teixeira, Manuel R , Thull, Darcy L , Tischkowitz, Marc D. , Toland, Amanda Ewart , Tommasi, Stefania , Toss, Angela , Tripathi, Vishakha , Valentini, Virginia , van Asperen, Christi J , Venturelli, Marta , Viel, Alessandra , Joseph, Vijai , Whaite, Anna , Simard, Jacques , Easton, Doug , Chenevix-Trench, Georgia , Ottini, Laura , Barnes, Daniel R , Leslie, Goska , Pujana, Miquel Angel , Eeles, Rosalind A , Evans, D Gareth , Matricardi, Laura , Olopade, Olufunmilayo I , Silvestri, Valentina , De Leeneer, Kim , Feliubadaló, Lidia , Hansen, Thomas van Overeem , Manoukian, Siranoush , Arnold, Norbert , Auber, Bernd , Balmañà, Judith , Barwell, Julian , Benı́tez, Javier , Bozsik, Anikó , Brady, Angela F., Buys, Saundra S. , Caligo, Maria A. , Campbell, Ian , Collaborators, GEMO Study, Collaborators, EMBRACE, Cook, Jackie A , Hoya, Miguel de la , Dı́ez, Orland , Domchek, Susan M. , Gallagher, David James , Hentschel, Julia , Investigators, KConFab, Investigators, HEBON, Izquierdo, Á. , Lázaro, Conxi , Lesueur, Fabienne , Mai, Phuong L, Maxwell, Kara N. , Meindl, Alfons , Nevanlinna, Heli , Nguyen‐Dumont, Tú , Palli, Domenico , Parsons, Michael T. , Radice, Paolo , Robson, Mark E. , Rump, Andreas , Singer, Christian F. , Stoppa‐Lyonnet, Dominique , Asperen, Christi J. van , Vijai, Joseph , Zanna, Ines , Couch, Fergus J. , Ottini, Laura

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 26, 2021 | Volume: 114 | Issue: 1 | Pages: 109-122

10.1093/jnci/djab147 | PMID 34320204 Get It

AbstractBackgroundRecent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers.Methods483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)–negative (PRSER-), or ER-positive (PRSER+) breast cancer risk.ResultsPRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions.ConclusionsPopulation-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
Ganesh, Ravindra , Bierle, Dennis M. , Anderson, Ryan J. , Arndt, Lori L., Arndt, Richard , Culbertson, Tracy L, Borgen, Molly J. Destro, Hanson, Sara N. , Kennedy, Brian , Kottke, Brian B, Larsen, Jennifer J., Ramar, Priya , Rosedahl, Jordan K., Seville, Maria Teresa , Speicher, Leigh L. , Tulledge‐Scheitel, Sidna M. , Wilker, Caroline G. , Arndt, Richard F, Destro Borgen, Molly J, Kennedy, Brian D, Tulledge-Scheitel, Sidna M, Razonable, Raymund R , Ganesh, Ravindra , Philpot, Lindsey M. , Razonable, Raymund R.

Mayo Clinic

The Journal of Infectious Diseases | July 17, 2021 | Volume: 224 | Issue: 8 | Pages: 1278-1286

10.1093/infdis/jiab377 | PMID 34279629 Get It

Abstract Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes. Methods Adult patients who received monoclonal antibody from 19 November 2020 to 11 February 2021 were selected and divided into those who received bamlanivimab (n = 2747) and casirivimab-imdevimab (n = 849). The 28-day all-cause and COVID-19–related hospitalizations were compared between the groups. Results The population included 3596 patients; the median age was 62 years, and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All-cause and COVID-19–related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all-cause and COVID-19–related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted hazard ratios [95% confidence interval], 1.4 [.9–2.2] and 1.6 [.8–2.7], respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization. Conclusions This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
Outcomes of Kidney Transplant Recipients with Sickle Cell Disease: An Analysis of the 2000–2019 UNOS/OPTN Database
Leeaphorn, Napat , Vaitla, Pradeep , Hansrivijit, Panupong , Jadlowiec, Caroline C. , Chewcharat, Api , Katari, Sreelatha , Pattharanitima, Pattharawin , Kaewput, Wisit , Mao, Michael A. , Cooper, Matthew , Cheungpasitporn, Wisit , Vaitla, Pradeep K , Hansrivijit, Panupong , Jadlowiec, Caroline , Mao, Shennen A. , Chewcharat, Api , Pattharanitima, Pattharawin , Mao, Michael A , Cooper, Matthew , Cheungpasitporn, Wisit , Kaewput, Wisit , Thongprayoon, Charat , Boonpheng, Boonphiphop

Mayo Clinic

Journal of Clinical Medicine | July 12, 2021 | Volume: 10 | Issue: 14 | Pages: 3063

10.3390/jcm10143063 | PMID 34300230 Get It

Background: Lower patient survival has been observed in sickle cell disease (SCD) patients who go on to receive a kidney transplant. This study aimed to assess the post-transplant outcomes of SCD kidney transplant recipients in the contemporary era. Methods: We used the OPTN/UNOS database to identify first-time kidney transplant recipients from 2010 through 2019. We compared patient and allograft survival between recipients with SCD (n = 105) vs. all other diagnoses (non-SCD, n = 146,325) as the reported cause of end-stage kidney disease. We examined whether post-transplant outcomes improved among SCD in the recent era (2010–2019), compared to the early era (2000–2009). Results: After adjusting for differences in baseline characteristics, SCD was significantly associated with lower patient survival (HR 2.87; 95% CI 1.75–4.68) and death-censored graft survival (HR 1.98; 95% CI 1.30–3.01), compared to non-SCD recipients. The lower patient survival and death-censored graft survival in SCD recipients were consistently observed in comparison to outcomes of recipients with diabetes, glomerular disease, and hypertension as the cause of end-stage kidney disease. There was no significant difference in death censored graft survival (HR 0.99; 95% CI 0.51–1.73, p = 0.98) and patient survival (HR 0.93; 95% CI 0.50–1.74, p = 0.82) of SCD recipients in the recent versus early era. Conclusions: Patient and allograft survival in SCD kidney recipients were worse than recipients with other diagnoses. Overall SCD patient and allograft outcomes in the recent era did not improve from the early era. The findings of our study should not discourage kidney transplantation for ESKD patients with SCD due to a known survival benefit of transplantation compared with remaining on dialysis. Urgent future studies are needed to identify strategies to improve patient and allograft survival in SCD kidney recipients. In addition, it may be reasonable to assign risk adjustment for SCD patients.
A core outcome set for the treatment of pregnant women with pregestational diabetes: an international consensus study
Kgosidialwa, Oratile , Bogdanet, Delia , Egan, Aoife M. , O’Shea, Paula , Newman, Christine , Griffin, Tomás P. , McDonagh, C, O'Shea, C, Carmody, Louise , Cooray, Shamil D. , Anastasiou, E., Wender‐Ożegowska, Ewa, Clarson, Cheril , Spadola, Alexandra, Alvarado, Fernanda , Noctor, Eoin , Dempsey, Eugene , Napoli, Angela , Galjaard, Sander , Loeken, Mary R. , Maresh, M., Gillespie, Paddy , Valk, Harold de, Biesty, Linda , Devane, Declan , Dunne, Fidelma , Kgosidialwa, O , Bogdanet, D , Egan, A M , Cooray, S D , O'Shea, Paula M , Gillespie, Paddy , Dunne, Fidelma P , Crowther, Caroline Anne , Agostini, Andrea , Newman, Christine

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | July 4, 2021 | Volume: 128 | Issue: 11 | Pages: 1855-1868

10.1111/1471-0528.16825 | PMID 34218508 Get It

Objective To develop a core outcome set (COS) for randomised controlled trials (RCTs) evaluating the effectiveness of interventions for the treatment of pregnant women with pregestational diabetes mellitus (PGDM). Design A consensus developmental study. Setting International. Population Two hundred and five stakeholders completed the first round. Methods The study consisted of three components. (1) A systematic review of the literature to produce a list of outcomes reported in RCTs assessing the effectiveness of interventions for the treatment of pregnant women with PGDM. (2) A three‐round, online eDelphi survey to prioritise these outcomes by international stakeholders (including healthcare professionals, researchers and women with PGDM). (3) A consensus meeting where stakeholders from each group decided on the final COS. Main outcome measures All outcomes were extracted from the literature. Results We extracted 131 unique outcomes from 67 records meeting the full inclusion criteria. Of the 205 stakeholders who completed the first round, 174/205 (85%) and 165/174 (95%) completed rounds 2 and 3, respectively. Participants at the subsequent consensus meeting chose 19 outcomes for inclusion into the COS: trimester‐specific haemoglobin A1c, maternal weight gain during pregnancy, severe maternal hypoglycaemia, diabetic ketoacidosis, miscarriage, pregnancy‐induced hypertension, pre‐eclampsia, maternal death, birthweight, large for gestational age, small for gestational age, gestational age at birth, preterm birth, mode of birth, shoulder dystocia, neonatal hypoglycaemia, congenital malformations, stillbirth and neonatal death. Conclusions This COS will enable better comparison between RCTs to produce robust evidence synthesis, improve trial reporting and optimise research efficiency in studies assessing treatment of pregnant women with PGDM. Tweetable abstract 165 key stakeholders have developed #Treatment #CoreOutcomes in pregnant women with #diabetes existing before pregnancy.
Abstract 17268: Echocardiographic Predictors of Cardiopulmonary Exercise Test Performance in Hypertrophic Cardiomyopathy
Ball, Caroline , Hebl, Virginia B., Ong, Kevin , Siontis, Konstantinos C. , Olson, Thomas P. , Allison, Thomas G. , Ommen, Steve R. , Larsen, Carolyn , Ball, Caroline A, Geske, Jeffrey B.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.17268 Get It

Introduction: Patients with hypertrophic cardiomyopathy (HCM) have lower peak oxygen uptake (VO2) than healthy peers. The mechanism of peak VO2 limitation in HCM has not been fully elucidated. Hypothesis: We assessed the hypothesis that resting echocardiographic parameters are predictive of peak VO2 in HCM. Methods: A retrospective review of adult HCM patients seen at a tertiary referral center from 2006-2012 was performed. Patients who underwent a comprehensive echocardiogram and cardiopulmonary treadmill exercise test within 1 week were included. Multivariate modeling was used to identify predictors of peak VO2 adjusting for age, sex, body mass index, beta blocker use, diabetes, smoking, systolic blood pressure, and obstructive HCM. Results: Five hundred and forty one patients met the inclusion criteria. The average age was 52 +/- 0.65 years, 62% were male, 78% had obstructive HCM, and 42% were NYHA class III or IV. Independent predictors of peak VO2 included averaged left ventricular (LV) longitudinal peak systolic strain (p<0.01) and right ventricular systolic pressure (RVSP) (p<0.01) (Figure 1). Obstructive versus non-obstructive HCM, grade of diastolic dysfunction, LV mass and wall thickness, left atrial volume index, right ventricular dysfunction and moderate or greater mitral or tricuspid regurgitation were not independent predictors of peak VO2. Conclusions: In conclusion, higher RVSP and less negative LV longitudinal peak systolic strain were moderate independent predictors of lower peak VO2. These findings confirm the hypothesis that resting echocardiographic parameters are predictive of peak VO2 in HCM. Further study of the relationship between echocardiographic findings and outcomes on cardiopulmonary exercise testing may help elucidate the mechanisms of exercise limitation in HCM.
Abstract 16775: Body Mass Index Predicts Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
Ball, Caroline , Hebl, Virginia B., Ong, Kevin , Siontis, Konstantinos C. , Olson, Thomas P. , Ommen, Steve R. , Allison, Thomas G. , Ball, Caroline A, Larsen, Carolyn , Geske, Jeffrey B.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.16775 Get It

Introduction: Impaired peak VO2 and obesity are known predictors of morbidity and mortality in Hypertrophic Cardiomyopathy (HCM). The purpose of this study is to determine the degree of exercise impairment due to excess weight in patients with HCM. Methods: Adult HCM patients who underwent cardiopulmonary treadmill testing at our tertiary referral center from 2006 - 2012 and had consented to research participation were identified retrospectively. Percent predicted peak VO2 was calculated by the Astrand formula for men and the Jones formula for women which adjust for age and gender. Baseline echocardiographic features obtained within 1 week of exercise testing and % predicted peak VO2 were compared among four groups of patients stratified by body mass index (BMI). Results: 510 patients were identified, with a mean age at diagnosis of 44.3 ± 16.1 years, 186 (36.5%) female. Mean BMI at the time of cardiopulmonary exercise testing was 29.7 ± 5.3 and 227 (44.6%) patients had a BMI ≥ 30. Overweight and obese patients were older and were more likely to be male than their normal weight peers. However, there was no significant difference in ejection fraction (EF), resting left ventricular outflow tract gradient, right ventricular systolic pressure (RVSP), or septal thickness among the groups. HCM patients show impaired peak VO2 across all BMI groups. While peak VO2 increased progressively across BMI groups consistent with greater O2 demand generated by higher body weight, the adjusted peak VO2 in mL/kg/min fell progressively, indicating progressively greater performance impairment with increasing BMI despite similar degrees of cardiac impairment (p <0.0001) (Table 1). Conclusion: Increased BMI is associated with reduced exercise performance in a graded manner in HCM patients independent of cardiac impairment identified on echocardiography.